Join FORVIS as we provide a tax legislation update on Internal Revenue Code (IRC) Section 174, including the new requirements to capitalize research and development costs. Our presenters will discuss implications to technology and life science companies beginning in 2022, including the new requirements’ impact on quarterly estimated tax payments, cash flows, and financial statements.
Upon completion of this program, participants will be able to:
- Plan for immediate and long-term impacts
- Analyze the operational impact
- Understand the nuances of ambiguous areas related to the IRC Section 174 changes
- Analyze cash flow impact for companies held by private equity firms